An extended regimen for treatment of HER-2/neu overexpressed/amplified cancer is described, with involves delivering a course of neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of surgical and adjuvant therapy. The neratinib regimen may be continued for upwards of twelve months to five years. Also provided are pharmaceutical kits designed to facilitate compliance with the regimen.本發明描述一種治療HER-2/neu過度表現/擴增之癌症之延伸療法，其涉及在手術及輔助療法完成後，對HER-2/neu過度表現/擴增之癌症病患進行投與來納替尼之療法。該來納替尼療法可持續長達12個月至5年。本發明亦提供經設計以促進該療法之投藥順服性之醫藥套組。
